The Surya Pharmaceuticals Multi-Bank Fraud
A Delhi-based drugmaker allegedly siphoned funds through group companies, defrauding Punjab & Sind Bank and four other lenders of over ₹620 crore — a case that surfaced just as Indian banks were tightening scrutiny after the Nirav Modi scandal broke.
The Promise
“Credit facilities extended to Surya Pharmaceuticals would be used for their stated business purposes and repaid according to sanctioned terms, as required under the consortium lending agreement.”
— Surya Pharmaceuticals Ltd and its promoters, borrowing from a consortium including Punjab & Sind Bank, Delhi-based pharmaceutical company and consortium borrower · 18 April 2018
This reflects the standard borrower obligation under consortium lending covenants rather than a specific loan agreement this entry has reviewed directly.
The Standard
Repayment of consortium credit facilities according to sanctioned terms, without diversion of borrowed funds to group companies or misrepresentation of the company's financial position.
RBI's fraud-classification norms for non-performing asset accounts and standard consortium lending covenants.
In force from 18 April 2018
The Reality
Punjab & Sind Bank filed a complaint alleging that Surya Pharmaceuticals, its two promoters, and a Dubai-based company defrauded it and four other banks of a combined amount reported at around ₹621 crore (US$94.57 million at the time), allegedly by siphoning off borrowed funds through group companies. The CBI opened an investigation in April 2018 — reported at the time as coming amid heightened bank vigilance following the Nirav Modi–Punjab National Bank scandal that had surfaced earlier that year — and conducted searches at seven locations, recovering documents. This investigation has not located reporting confirming a subsequent chargesheet, trial outcome, or recovery status.
As of 18 April 2018
The Gap
Bars share a single zero-based scale. No axis truncation is used to exaggerate or minimize the gap between the two figures.
Timeline
- MilestoneCBI opens investigation
Following a Punjab & Sind Bank complaint, the CBI begins probing Surya Pharmaceuticals over alleged fraud against a five-bank consortium.
- StatusCBI conducts searches
Searches at seven locations recover documents related to the alleged fund diversion.
Legal Status
This is a stub entry. The CBI opened an investigation and conducted searches in April 2018; this investigation has not established whether a chargesheet was subsequently filed or the case's current status.
Verdict
Preliminary verdict, pending fuller research: the ₹621 crore multi-bank fraud allegation, Punjab & Sind Bank's complaint, and the CBI's initial investigation and searches are documented from contemporaneous reporting. This investigation has not established the case's subsequent trajectory.
This entry is based on a single contemporaneous 2018 wire report; it has not located independent confirmation of a chargesheet, trial, or verdict in the years since, which may reflect either limited subsequent media coverage or a genuine stall in the case.
What remains incomplete
- This is a stub entry, based primarily on a single 2018 report of the CBI's initial investigation and searches.
- It is not established whether a CBI chargesheet was filed, or what the case's current status is as of 2026.
- The names of Surya Pharmaceuticals' promoters named in the complaint have not been confirmed in sources reviewed for this entry.
Sources
Related investigations
The Mahadev Betting App Scam
An illegal online betting platform allegedly built a ₹6,000 crore empire with political protection in Chhattisgarh. Its promoter is now the subject of an Interpol Red Notice, detained abroad as India seeks his extradition.
The Sahara–SEBI Case
A conglomerate raised tens of thousands of crores from small investors through bonds regulators later ruled illegal. Its chairman spent years in custody over the refund dispute and died before it was fully resolved.
The Satyam Computers Scam
The chairman of one of India's biggest IT companies confessed, in a letter to his own board, to inflating profits and fabricating a cash balance for years — a confession that instantly became India's best-known corporate accounting fraud.